Insitro — Valuation, Funding & Investors

Insitro is a biotechnology company, founded and led by AI pioneer Daphne Koller, that combines more than 20 petabytes of automated cellular experiments with population-scale genetics to identify the causal drivers of human disease. It is headquartered in the United States and describes its mission as bringing better drugs faster to the patients who can benefit most through machine learning and data at scale.

Its TherML platform is a modality-agnostic therapeutics design engine spanning small molecules, oligonucleotides and complex biologics, matching the best-fit modality to each drug target. In January 2026, insitro acquired CombinAbleAI to expand its AI drug discovery work and support the launch of TherML.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Insitro.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Insitro availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Insitro included.

The routes section explains what is realistically available for a company at this stage.

No. Insitro was acquired by CombinAble.AI Biotech firm combining automated cellular experiments and population genetics with AI to identify disease drivers and deliver targeted therapeutics; its shares do not trade independently.

The last valuation is $2.4B.

Lead investors for each round are in the funding timeline.

The closest biotechnology peers are on the competitors page.